Clinical trial · Interventional
Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No participants enrolled
Summary
Brief summary (as posted)
Objectives: This protocol is part of a larger grant funded by the NCI to create an international research center to study Traditional Chinese Medicine (TCM). All of the patients enrolled in this study will be treated at the Cancer Hospital, Fudan University, investigator's sister institution in Shanghai, China. No patients will be seen at MDACC. This protocol will be overseen by the Fudan University Institutional Review Board (IRB00002408) which has Federal Wide Assurance through the U.S. Department of Health \& Human Services (Approved: April 25, 2002). The research nurses have received training at MDACC and will receive regular oversight by MDACC personnel. The purpose of this randomized, placebo controlled study is to determine the effects of K1 acustimulation at controlling chemotherapy induced nausea and vomiting (CINV). 1. The primary aim of this study is to determine the effects of electro-stimulation of Yongquan (K1) acupoint on preventing nausea and vomiting induced by cisplatin or oxaliplatin. 2. The secondary aim is to observe the effects of electro-stimulation (ES) of Yongquan (K1) acupoint on pain, insomnia, abdominal distention, dizziness, and general sense of well-being.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Liver Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electro-Stimulation of Yongquan (K1) Acupoint | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Electro-Stimulation (Active Site)
- description
- Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
- interventionNames
- Procedure: Electro-Stimulation of Yongquan (K1) Acupoint
- type
- EXPERIMENTAL
- label
- Electro-Stimulation (Inactive Site)
- description
- Electro-stimulation at a inactive site on the bottom of the foot (a "placebo" site).
- interventionNames
- Procedure: Electro-Stimulation of Yongquan (K1) Acupoint
Primary outcomes (1)
- measure
- Level of Patient Nausea + Vomiting
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. All patients who will undergo TAI (transarterial infusion) for liver primary or other primary with liver metastasis 2. Between 18-75 years old 3. Patients who will receive TAI using cisplatin or oxaliplatin 4. Must give informed consent 5. If patients is female and of child bearing potential, must have a negative urine pregnancy test Exclusion Criteria: 1. Has local skin infections at or near the acupoints 2. Previous TAI treatment using platinum-based chemotherapy 3. History of cerebrovascular or cardiovascular accident or spinal cord injury 4. Nausea and vomiting induced by intestinal obstruction 5. Has cardiac pacemaker 6. Mental incapacitation or significant emotional or psychiatric disorder that, in the opinion of the investigator, precludes study entry as these patients may not be able to cooperate with this slightly invasive procedure or with the data collection process 7. Currently using acupuncture 8. Vomiting or using 5-HT3 receptor antagonists or other antiemetic in 24 hours before TAI.
References
Publications (0)
Data not yet available